Expert: New Guidance May Demand Clinical Decision Support Software Re-Evaluation
Executive Summary
Businesses should reevaluate the classification of their clinical decision software based on a new FDA guidance, Kyle Faget of Foley & Lardner LLP tells Medtech Insight.
You may also be interested in...
CDS Final Guidance Draws More Criticism, This Time From Congress
Senator Bill Cassidy says FDA “disregarded” Congressional intent by expanding its authority to regulate clinical decision support software.
Don’t Worry, You (Probably) Won’t Have To Deal With ONC: Algorithm Transparency Rule May Have Surprise Effects On Medtech Firms
Epstein Becker Green attorney Alaap Shah breaks down the HHS ONC’s 800-page rule on algorithm transparency and information blocking.
Abiomed Letter Underscores Questions On FDA’s Clinical Decision Support Guidance
A warning letter from the US FDA to device manufacturer Abiomed highlights industry’s criticism that the agency’s final guidance on clinical decision support software is flawed and oversteps regulatory boundaries.